Core Viewpoint - The company, Borui Pharmaceutical (688166.SH), announced that the interest payment for its convertible bonds issued on January 4, 2022, will commence on January 5, 2026, due to January 4, 2026, being a non-trading day [1] Group 1 - The interest payment marks the fourth year of interest for the "Borui Convertible Bonds" [1] - The interest accrual period is from January 4, 2025, to January 3, 2026 [1] - The coupon rate for this interest year is set at 1.5% (tax included), resulting in an interest payment of 15 RMB (tax included) for each bond with a face value of 1,000 RMB [1]

（文章来源：证券日报） 证券日报网讯 12月15日晚间，博瑞医药发布公告称，截至本公告披露日，公司已完成本次股份回购。 公司通过上海证券交易所交易系统以集中竞价交易方式累计回购公司股份196，871股，占公司总股本的 0.0465%。 ...

每经AI快讯，博瑞医药（SH 688166，收盘价：49.94元）12月15日晚间发布公告称，截至本公告披露 日，公司已完成本次股份回购。公司通过上海证券交易所交易系统以集中竞价交易方式累计回购公司股 份约20万股，占公司总股本的0.0465%，回购成交的最高价为54.28元/股、最低价为49.81元/股，支付的 资金总额为人民币约1004万元。 每经头条（nbdtoutiao）——"一针两千，童颜针年销3亿元"背后：多家关联方注册地"查无此人"，股民 追问"钱呢"！钱氏姐弟几乎"掏空"江苏吴中，公司即将退市 （记者 王晓波） 2024年1至12月份，博瑞医药的营业收入构成为：医药制造业占比97.33%，其他业务占比2.67%。 截至发稿，博瑞医药市值为211亿元。 ...

格隆汇12月15日丨博瑞医药(688166.SH)公布，截至本公告披露日，公司已完成本次股份回购。公司通 过上海证券交易所交易系统以集中竞价交易方式累计回购公司股份19.69万股，占公司总股本的 0.0465%，回购成交的最高价为54.28元/股、最低价为49.81元/股，支付的资金总额为人民币1003.78万元 （不含印花税、交易佣金等交易费用）。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 回购方案首次披露日 | 2025/9/27，由公司控股股东、实际控制人、董事 | | | | | | --- | --- | --- | --- | --- | --- | | | 长袁建栋先生提议 | | | | | | 回购方案实施期限 | 年 日~2026 月 2025 9 26 9 | 月 | 年 | 25 | 日 | | 预计回购金额 | 1,000万元~2,000万元 | | | | | | 回购价格上限 | 139.77元/股 | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | | | | | 实际回购股数 | 19.6871万股 | | | | | | 实际回购股数占总股本比例 | 0.0465% | | | | | | 实际回购金额 | 1,003.78万元 | | | | | | 实际回购价格区间 | 49.81元/股~54.28元/股 | ...

格隆汇12月15日丨博瑞医药(688166.SH)公布，截至本公告披露日，公司已完成本次股份回购。公司通 过上海证券交易所交易系统以集中竞价交易方式累计回购公司股份19.69万股，占公司总股本的 0.0465%，回购成交的最高价为54.28元/股、最低价为49.81元/股，支付的资金总额为人民币1003.78万元 （不含印花税、交易佣金等交易费用）。 ...

Group 1 - The A-share market experienced fluctuations with the innovative drug sector showing a rebound before retreating, as evidenced by the performance of the Science and Technology Innovation Drug ETF Huatai (589120) which was flat after initially rising over 1% [1] - The Science and Technology Innovation Drug ETF Huatai (589120) has seen net inflows exceeding 9.39 million yuan over the past five days, with funds entering the market intermittently [1] - The component stocks of the ETF showed mixed performance, with stocks like Ailisi and Baili Tianheng rising over 1%, while others like Maiwei Biology fell over 2% [3][4] Group 2 - The 2025 National Basic Medical Insurance Drug Directory has been adjusted, adding 114 new drugs, including 50 first-class innovative drugs, which reflects ongoing support for innovation in the pharmaceutical sector [5][6] - The adjustment of the drug directory aims to encourage innovation while ensuring basic healthcare needs, with a focus on "true innovation" and "differentiated innovation" [6] - The commercial insurance directory has included 19 drugs, including CAR-T and treatments for Alzheimer's disease, indicating a significant step towards expanding commercial medical insurance in China [6] Group 3 - The innovative drug sector is expected to maintain a high level of activity, with a focus on "data validation" and "value reassessment" as key investment themes [6][7] - The industry is entering an internationalization phase, with business development (BD) becoming a regular practice, and the verification of global product value being crucial for future growth [7] - The Science and Technology Innovation Drug ETF Huatai (589120) focuses on leading innovative drug companies, providing a higher degree of exposure to the opportunities presented by the rise of innovative drugs in China [7]

Core Insights - The pharmaceutical sector is experiencing a rise, with the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index increasing by 1.03% as of December 4, 2025, with notable gains from companies like Zai Lab (up 4.47%) and Rongchang Bio (up 4.14%) [1] Industry Overview - The pharmaceutical industry has undergone eleven rounds of national drug centralized procurement and multiple rounds of medical insurance negotiations, leading to an inevitable decline in the generic drug sector, which impacts the overall pharmaceutical industry [1] - From January to September 2025, the pharmaceutical manufacturing industry's revenue remained relatively stable, but the outlook for generic drugs is bleak, indicating a need for innovative drugs to drive future growth [1] Investment Perspective - According to Everbright Securities, future investments in the pharmaceutical sector should focus on the clinical value of drugs, addressing clinical needs of patients, as both domestic medical insurance policies and global expansion strategies increasingly emphasize clinical value [1] - The innovative drug industry chain and innovative medical devices are viewed positively based on the clinical value framework [1] Market Data - As of November 28, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index include companies like United Imaging Healthcare and BeiGene, collectively accounting for 49.75% of the index [1]

（文章来源：证券日报） 证券日报网讯 12月2日，博瑞医药在互动平台回答投资者提问时表示，公司会在定期报告中披露法定要 求的股东数量信息。 ...

Group 1 - The core point of the article is that Borui Pharmaceutical has received a drug registration certificate for its inhaled Budesonide suspension, indicating progress in its approval process [1] Group 2 - Investors inquired about the approval status of Budesonide on an interactive platform [1] - Borui Pharmaceutical confirmed the approval and mentioned that detailed information can be found in the company's Q3 2025 report [1]